<?xml encoding="utf-8" ?> Ophthalmic disease management company Harrow Inc. HROW on Thursday shared outcomes from a ...

Patients reported approximately 58% less discomfort overall in the IHEEZO-treated eye, with the largest absolute differences in the immediate post-injection period, when discomfort is highest ...

Harrow (HROW) said Thursday that IHEEZO reduced patient-reported discomfort by about 58% compared with proparacaine in a prospective study of patients undergoing same-day bilateral intravitreal ...

Boll stated, "we are updating our full year revenue outlook to a range of $270 million to $280 million." He noted, "While our original target is still within reach, this new range is one I believe we ...

Lachlan Hanbury-Brown, William Blair: asked if TYRVAYA should be prorated into 2026 and EBITDA impact; President, CFO Boll: "that's a fair assessment to kind of pro rata" and "we don't expect it to ...

On August 10, Harrow Inc. (NASDAQ:HROW) walked investors through a first half that fell short and a back half that now has to make up the difference. Revenue for the first six months of 2026 came in ...

According to reports, on August 6, Harrow, Inc. (NASDAQ:HROW) announced a definitive agreement to acquire global rights to ...

Harrow Inc (NASDAQ:HROW) and Taiwan-based Formosa Pharmaceuticals announced a licensing agreement on Monday. Harrow acquired the exclusive U.S. commercial rights for BYQLOVI (clobetasol propionate ...

Harrow (HROW) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to earnings of $0.24 per share a year ago. These figures are ...

Harrow has the U.S. commercial rights to 10 branded ophthalmic pharmaceutical products approved by the Food and Drug Administration (FDA). Harrow also owns ImprimisRx, a leading U.S.

Was the transaction executed via direct or indirect ownership, and what entities were involved? All shares were disposed of indirectly through Opaleye, L.P. and a separately managed account, with ...